REG - T.Rowe Price Assoc - Form 8.3 - [AbbVie Inc]

T Rowe PriceAnnouncement

12/03/2020 14:05

RNS Number : 9534F
  
T.Rowe Price Associates
  
12 March 2020
  
 

Ap19
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


 T. ROWE PRICE ASSOCIATES, INC.




Company dealt in


 ABBVIE INC




Class of relevant security to which the dealings being disclosed relate (Note 2)


 ISIN: US00287Y1091 




Date of dealing


 11 March 2020




2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 45,540,168                3.07%


 




(2) Derivatives (other than options)


 


 




(3) Options and agreements to purchase/sell


  


 




Total


 45,540,168                3.07%


 



 
 
 
 
 
 
 



 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)




Class of relevant security:


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 


 




 
(2) Derivatives (other than options)


 


 




 
(3) Options and agreements to purchase/sell


 


 




Total


 


 



 
 
 
 
 
 
 




 

Ap20
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




 
Purchase/sale


 
Number of relevant securities


 
Price per unit (Note 5)




Purchases
 
 
 
 
 
 
 
 
 
Sales
 
 
 
 
 
 
 
 


6,539
10,977
2,100
28,145
283,971
300
34,485
25
500
6,321
10,700
17,120
540
7,200
244
2,400
31
7,600


83.964 USD
84.119 USD
84.216 USD
84.850 USD
84.879 USD
85.245 USD
85.407 USD
85.640 USD
85.681 USD
86.283 USD
84.121 USD
84.157 USD
84.252 USD
84.373 USD
84.850 USD
85.270 USD
85.595 USD
86.260 USD
 
 
 
 
 
 




 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)




 


 


 


 




 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 





 

Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and 
any other person relating to the voting rights of any relevant securities under any option referred to 
on this form or relating to the voting rights or future acquisition or disposal of any relevant 
securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 
 
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


 12 March 2020




Contact name


 Gary Greb




Telephone number


 001 410 345 2527




If a connected EFM, name of offeree/offeror with which connected


 




If a connected EFM, state nature of connection (Note 10)


 




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEUURORRRUOAAR